Higher CD4 counts were also associated with decreased mortality but over the five year period, the rise in median CD4 count for patients who were not on ART at the start of TB treatment was modest indicating that the improved mortality was most likely driven by the considerable increase in ART uptake (37.0 to 77.7%). The gene discussed is CD4; the disease is tuberculosis.